Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

(2018) Angeliki M. Stamatouli et al.   DIABETES

Autoimmune Polyendocrine Syndromes

(2018) Eystein S. Husebye et al.   NEW ENGLAND JOURNAL OF MEDICINE

Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab

(2018) Kanako Sakurai et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

(2017) Hye In Kim et al.   OncoImmunology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes

(2016) Sung Hye Kong et al.   ACTA DIABETOLOGICA

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome

(2016) Elizabeth Hansen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

(2016) Jared R. Lowe et al.   Journal for ImmunoTherapy of Cancer

Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

(2015) Mahnaz Mellati et al.   DIABETES CARE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Autoimmune polyglandular syndrome type 2 shows the same HLA class II pattern as type 1 diabetes†

(2011) C. Weinstock et al.   TISSUE ANTIGENS